细胞表面波形蛋白阳性循环肿瘤细胞在小儿肉瘤中的预后价值
Prognostic Value of Cell-Surface Vimentin-Positive CTCs in Pediatric Sarcomas.
作者信息
Dao Long, Ragoonanan Dristhi, Batth Izhar, Satelli Arun, Foglesong Jessica, Wang Jian, Zaky Wafik, Gill Jonathan B, Liu Diane, Albert Aisha, Gordon Nancy, Huh Winston, Harrison Douglas, Herzog Cynthia, Kleinerman Eugenie, Gorlick Richard, Daw Najat, Li Shulin
机构信息
Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
出版信息
Front Oncol. 2021 Dec 9;11:760267. doi: 10.3389/fonc.2021.760267. eCollection 2021.
BACKGROUND
Despite advances in care, the 5 year overall survival for patients with relapsed and or metastatic sarcoma remains as low as < 35%. Currently, there are no biomarkers available to assess disease status in patients with sarcomas and as such, disease surveillance remains reliant on serial imaging which increases the risk of secondary malignancies and heightens patient anxiety.
METHODS
Here, for the first time reported in the literature, we have enumerated the cell surface vimentin (CSV+) CTCs in the blood of 92 sarcoma pediatric and adolescent and young adult (AYA) patients as a possible marker of disease.
RESULTS
We constructed a ROC with an AUC of 0.831 resulting in a sensitivity of 85.3% and a specificity of 75%. Additionally, patients who were deemed to be CSV+ CTC positive were found to have a worse overall survival compared to those who were CSV+ CTC negative. We additionally found the use of available molecular testing increased the accuracy of our diagnostic and prognostic tests.
CONCLUSIONS
Our findings indicate that CSV+ CTCs have prognostic value and can possibly serve as a measure of disease burden.
背景
尽管在治疗方面取得了进展，但复发和/或转移性肉瘤患者的5年总生存率仍低至<35%。目前，尚无生物标志物可用于评估肉瘤患者的疾病状态，因此，疾病监测仍依赖于系列影像学检查，这增加了继发恶性肿瘤的风险并加剧了患者的焦虑。
方法
在此，我们首次在文献中报道，我们对92例儿科、青少年和青年（AYA）肉瘤患者血液中的细胞表面波形蛋白（CSV+）循环肿瘤细胞（CTC）进行了计数，将其作为一种可能的疾病标志物。
结果
我们构建了一个曲线下面积（AUC）为0.831的受试者工作特征（ROC）曲线，灵敏度为85.3%，特异性为75%。此外，与CSV+ CTC阴性的患者相比，被认为CSV+ CTC阳性的患者总生存率更差。我们还发现，使用现有的分子检测提高了我们诊断和预后检测的准确性。
结论
我们的研究结果表明，CSV+ CTC具有预后价值，并可能作为疾病负担的一种衡量指标。
Zotero 插件